Edwards Lifesciences Eyes Growth with TAVR Expansion and Heart Valve Innovations

Edwards Lifesciences is anticipating a boost in sales with the mid-2025 approval of an expanded indication for its Sapien TAVR system in asymptomatic patients with severe aortic stenosis. During an investor day event, Edwards outlined how this approval, combined with rapid growth in its mitral and tricuspid heart valve technologies, will drive company sales starting in 2026. The expanded indication is expected to lead to revised treatment guidelines, enabling earlier intervention and improved patient outcomes. Additionally, Edwards is progressing with new treatments for heart valve diseases, including the transcatheter mitral valve replacement system, which could gain European approval by mid-2025.

Looking further ahead, Edwards is also focused on advancing its heart failure solutions, such as the Cordella pulmonary artery pressure sensor, and expects significant growth in sales of transcatheter mitral and tricuspid therapies (TMTT). The company predicts TAVR sales will increase by 5% to 7% in 2025, and TMTT sales could rise by 50% to 60%. With total sales projected to grow by 8% to 10% in 2025, Edwards is targeting an ambitious 10% annual growth beginning in 2026, aiming for a $2 billion TMTT sales figure by 2030.